News EMA experts will look again at Leqembi's safety data It seems Eisai and Biogen have another hurdle to jump over in their bid to get EU approval for their Alzheimer's disease therapy Leqembi.
News Large study points to benefits - and risks - of GLP-1 drugs The largest observational study of GLP-1 weight-loss drugs suggests their benefits could be wide-ranging, but there are some risks to consider.
News FDA bans red dye used in medicines over cancer risk The FDA has banned the use of a red dye used in oral medicines, foods and dietary supplements, more than 30 years after it was linked to cancer.
News Keros pulls study of Winrevair rival after safety signal Adverse events have led Keros to abandon a phase 2 trial of pulmonary arterial hypertension drug cibotacept, a would-be rival to MSD's Winrevair.
News Safety fear halts Keros PAH trial dosing, hitting its shares An unexpected side effect has led Keros to halt dosing in two arms of its phase 2 trial of pulmonary arterial hypertension drug cibotercept.
News Fresh from IPO, obesity drug developer BioAge hits a hurdle Liver safety signal leads BioAge to discontinue its phase 2 trial of obesity candidate azelaprag, hitting the Nasdaq debutante's share price.
News USAID could see workforce cut to 600 as stop-work looms The Trump administration intends to keep only 611 essential workers at USAID, according to media reports - unless a lawsuit thwarts the plans.
Sales & Marketing Sponsored Health Trends 2025: Reimagining What's Possible Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl